Bigalke R D
Veterinary Research Institute, Onderstepoort.
Onderstepoort J Vet Res. 1987 Sep;54(3):543-6.
This article highlights the most important research goals identified during the workshop on "Heartwater: Past, Present and Future," which was held from 8-11 September 1986 in the Republic of South Africa. An attempt has also been made to identify the most modern technology which is available for this purpose. All 60 papers presented at the workshop, together with other relevant information, are published in this number of the Onderstepoort Journal of Veterinary Research. With regard to the causative organism it is crucial that research should be conducted on pure isolates. Moreover, existing culture methods should be improved in order to obtain better yields of organisms. Research on the hosts and vectors of Cowdria ruminantium should aim to elucidate the ways in which vector ticks become infected in nature. For this purpose especially, it will be necessary to develop rapid tests (e.g. DNA probes) to detect the organism in living animals and ticks. The nature of immunity and young animal resistance are still obscure and call for basic research. Mice and murino-tropic isolates of C. ruminantium should prove useful in this regard. Since cross-reactions with Ehrlichia occur, it is essential to give particular attention to the sero-epidemiology of Ehrlichia in conjunction with similar studies on Cowdria. The development of a tissue culture vaccine offers the greatest chance of immediate success and should be actively pursued. Studies on a recombinant vaccine should, however, be initiated because of the potential long term advantages.
本文重点介绍了1986年9月8日至11日在南非共和国举行的“心水病:过去、现在与未来”研讨会上确定的最重要研究目标。同时还尝试确定可用于此目的的最现代技术。研讨会上发表的所有60篇论文以及其他相关信息均刊载于本期《 Onderstepoort兽医研究杂志》。关于病原体,对纯分离株进行研究至关重要。此外,应改进现有的培养方法,以提高病原体的产量。对反刍动物考德里氏体的宿主和传播媒介的研究应旨在阐明传播媒介蜱在自然环境中感染的方式。尤其为此,有必要开发快速检测方法(如DNA探针)以检测活体动物和蜱中的病原体。免疫的本质和幼畜的抵抗力仍不清楚,需要进行基础研究。在这方面,小鼠和嗜鼠性反刍动物考德里氏体分离株应会有所帮助。由于存在与埃立克体的交叉反应,因此在对考德里氏体进行类似研究的同时,必须特别关注埃立克体的血清流行病学。组织培养疫苗的开发最有可能立即取得成功,应积极推进。然而,鉴于其潜在的长期优势,应启动重组疫苗的研究。